CGBIO Receives FDA IDE Approval for NOVOSIS PUTTY, Advancing Toward U.S. Market Entry
- Written by PR Newswire
![]() |
- The bone graft incorporating rhBMP-2 has received FDA IDE approval for a pivotal clinical trial in spinal fusion- Positioned for global expansion in $750M spinal bone graft market
SEOUL, South Korea, April 24, 2025 /PRNewswire/ -- CGBIO(CEO Hyun Seung Yu), a leading Korean company specializing in bio-regenerative medicine,...
Read more: CGBIO Receives FDA IDE Approval for NOVOSIS PUTTY, Advancing Toward U.S. Market Entry















